Keros Therapeutics, Inc. (KROS): History, Ownership, Mission, How It Works & Makes Money

Ever wonder about the companies pioneering treatments for blood, pulmonary, and cardiovascular disorders? Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, stands out as a key player in this field, but how exactly does it operate and generate revenue? Keep reading to discover its history, ownership structure, mission, and business model, complete with insights into its 2024 financial performance, including a revenue of $3.55 million and a net loss of $187.35 million.

Keros Therapeutics, Inc. (KROS) History

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of hematological and pulmonary disorders with significant unmet medical need. The company's approach is centered on understanding and manipulating the transforming growth factor-beta (TGF-β) family of proteins, which play a crucial role in various biological processes, including cell growth, differentiation, and immune function. By targeting these pathways, Keros aims to develop treatments that can modify disease progression and improve patient outcomes.

[Company's] Founding Timeline

Year established

Keros Therapeutics was founded in 2015.

Original location

The company is headquartered in Lexington, Massachusetts.

Founding team members

Specific details about the founding team members are not available in the provided search results.

Initial capital/funding

Information regarding the initial capital or funding of Keros Therapeutics during its establishment is not available in the search results.

[Company's] Evolution Milestones

[Company's] Transformative Moments

• Focus on TGF-β Pathway: A key transformative decision was the strategic focus on the TGF-β family of proteins. This allowed Keros to target fundamental mechanisms underlying various diseases.
• Advancement of Clinical Programs: The progression of KER-050 and KER-047 into clinical trials marked a significant step, reflecting the company's ability to translate preclinical research into potential therapies.
• Strategic Partnerships and Collaborations: Forming collaborations to expand its research and development capabilities has been crucial in Keros's growth. Specific details of partnerships are not available in the search results.

To gain more insights into the company's financial stability, read this article: Breaking Down Keros Therapeutics, Inc. (KROS) Financial Health: Key Insights for Investors

Keros Therapeutics, Inc. (KROS) Ownership Structure

Understanding the ownership structure of Keros Therapeutics, Inc. (KROS) provides valuable insights into the company's control and governance.

Keros Therapeutics, Inc. (KROS) Current Status

Keros Therapeutics Inc. is a public company, trading on the Nasdaq Global Select Market under the ticker symbol KROS. This means that ownership is distributed among public shareholders, although a significant portion may be held by institutional investors, company insiders, and major individual shareholders.

Keros Therapeutics, Inc. (KROS) Ownership Breakdown

The ownership of Keros Therapeutics is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. While specific percentages may fluctuate, this table represents a general overview of the ownership structure based on the latest available data for the fiscal year 2024.

Keros Therapeutics, Inc. (KROS) Leadership

Keros Therapeutics is guided by a team of experienced leaders. Here are some key members of the leadership team:

• Pavinder S. Makker, MD: President and Chief Executive Officer
• Jayson Marret, MBA: Chief Financial Officer
• Ryan Dawsing, JD: Chief Legal Officer

For more detailed insights into Keros Therapeutics, Inc.'s financial standing, explore Breaking Down Keros Therapeutics, Inc. (KROS) Financial Health: Key Insights for Investors.

Keros Therapeutics, Inc. (KROS) Mission and Values

Keros Therapeutics aims to transform the lives of patients with hematological and pulmonary disorders by developing novel therapeutics that address the underlying causes of disease. The company is guided by a set of core values that emphasize scientific excellence, patient focus, and integrity.

Keros Therapeutics' Core Purpose

Official mission statement

To develop and commercialize novel therapeutics to treat hematological and pulmonary diseases with high unmet medical need.

• Keros Therapeutics focuses on developing treatments for hematological and pulmonary diseases.
• The company aims to address conditions where there is a significant lack of effective therapies.
• Keros Therapeutics is dedicated to creating and bringing to market new therapeutic options.

Vision statement

While a specific vision statement is not publicly available, Keros Therapeutics' corporate presentation from September 2023 outlines key strategic priorities that reflect the company's vision for the future:

• Advance clinical programs, particularly focusing on accelerating the development of investigational candidate KER-050 in myelodysplastic syndromes (MDS) and myelofibrosis (MF).
• Continue to expand the pipeline by leveraging the activin receptor-like kinase (ALK) 2 platform to develop treatments for pulmonary arterial hypertension (PAH) and other disorders.
• Presenting promising data from clinical trials to support regulatory submissions and potential approvals.

Company slogan/tagline

Keros Therapeutics does not have a widely publicized official slogan or tagline. However, their focus on pioneering treatments for hematological and pulmonary disorders encapsulates their commitment to innovation and patient care.

To gain more comprehensive insights into the values that drive Keros Therapeutics, explore: Mission Statement, Vision, & Core Values of Keros Therapeutics, Inc. (KROS).

Keros Therapeutics, Inc. (KROS) How It Works

Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for patients suffering from hematological and pulmonary disorders, often targeting the transforming growth factor-beta (TGF-β) superfamily.

Keros Therapeutics, Inc.'s Product/Service Portfolio

Keros Therapeutics, Inc.'s Operational Framework

Keros Therapeutics operates through a focused approach to drug development, leveraging its understanding of the TGF-β superfamily to create targeted therapies. Key aspects of their operational framework include:

• Target Identification and Validation: Identifying specific TGF-β superfamily ligands and receptors that play critical roles in disease pathways.
• Drug Development: Engineering novel protein therapeutics, such as ligand traps and monoclonal antibodies, designed to modulate the activity of these targets.
• Clinical Trials: Conducting rigorous preclinical and clinical trials to evaluate the safety and efficacy of their drug candidates. For instance, KER-050 has undergone Phase 2 clinical trials, and KER-047 is in Phase 2 trials.
• Partnerships and Collaborations: Engaging in strategic partnerships to support development and commercialization efforts.
• Regulatory Strategy: Working closely with regulatory agencies like the FDA to navigate the approval process.

Keros Therapeutics, Inc.'s Strategic Advantages

Keros Therapeutics, Inc. possesses several strategic advantages that underpin its market position and future growth potential:

• Targeted Therapies: Development of specific treatments for hematological and pulmonary disorders.
• Innovative Technology: Use of novel protein therapeutics like ligand traps and monoclonal antibodies.
• Clinical Validation: Advancing drug candidates through clinical trials to confirm safety and effectiveness.
• Experienced Team: Strong leadership and scientific expertise in TGF-β biology and drug development.

To gain more insights into the investors and motivations behind Keros Therapeutics, explore: Exploring Keros Therapeutics, Inc. (KROS) Investor Profile: Who’s Buying and Why?

Keros Therapeutics, Inc. (KROS) How It Makes Money

Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, primarily focusing on the discovery, development, and commercialization of novel therapeutics for the treatment of hematological and pulmonary disorders. The company generates revenue through strategic collaborations, licensing agreements, and potentially, future product sales.

[Company's] Revenue Breakdown

[Company's] Business Economics

The business economics of Keros Therapeutics are characterized by substantial investments in research and development (R&D). As a clinical-stage company, Keros Therapeutics does not yet have products on the market, making its financial sustainability heavily reliant on securing partnerships and achieving clinical milestones.

• R&D Expenses: A significant portion of the company's expenditure is allocated to R&D, which covers preclinical studies, clinical trials, and drug development efforts.
• Collaboration Agreements: Revenue is primarily derived from collaboration agreements with pharmaceutical companies, involving upfront payments, milestone payments, and potential royalties on future sales.
• Cash Runway: The company's financial health is closely monitored through its cash runway, indicating how long it can sustain operations before needing additional funding.

[Company's] Financial Performance

Keros Therapeutics' financial performance can be evaluated through several key metrics, reflecting its current stage of development and future potential.

• Revenue: For the year ended December 31, 2024, Keros Therapeutics reported total revenue of $25.8 million, a significant increase compared to $3.4 million for the same period in 2023. This increase was primarily due to revenue recognized under the collaboration agreement with Boehringer Ingelheim.
• Research and Development Expenses: R&D expenses for 2024 were $73.1 million, compared to $62.0 million in 2023. The increase was mainly attributed to higher clinical trial expenses, increased personnel costs, and greater manufacturing expenses.
• General and Administrative Expenses: General and administrative expenses totaled $24.4 million in 2024, up from $18.4 million in 2023, driven by increased personnel costs and professional fees.
• Net Loss: The company reported a net loss of $71.5 million for 2024, compared to a net loss of $77.9 million for 2023.
• Cash Position: As of December 31, 2024, Keros Therapeutics had cash, cash equivalents, and marketable securities totaling $294.0 million. This strong cash position is expected to fund operations into the second half of 2026.

For a deeper dive into the financial aspects, explore: Breaking Down Keros Therapeutics, Inc. (KROS) Financial Health: Key Insights for Investors

Keros Therapeutics, Inc. (KROS) Market Position & Future Outlook

Keros Therapeutics is strategically positioned to capitalize on the growing market for therapeutics targeting disorders related to transforming growth factor-beta (TGF-β) signaling pathways. With a focus on developing novel treatments for hematological and pulmonary diseases, Keros aims to address unmet medical needs and establish a strong foothold in the biopharmaceutical industry.

Competitive Landscape

Opportunities & Challenges

Industry Position

Keros Therapeutics is carving out a niche in the competitive biopharmaceutical landscape by focusing on specific TGF-β signaling pathways. This targeted approach allows for the development of potentially more effective and safer therapies compared to broad-spectrum treatments. The company's success hinges on:

• Advancing its clinical programs and demonstrating positive clinical outcomes.
• Securing strategic partnerships to support development and commercialization efforts.
• Effectively managing intellectual property and maintaining a competitive edge.

To gain more insights into the company's financial standing, consider exploring: Breaking Down Keros Therapeutics, Inc. (KROS) Financial Health: Key Insights for Investors